User login
Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.
Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.
Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.
Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.
Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z
Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.
Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.
Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.
Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.
Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z
Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.
Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.
Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.
Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.
Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z